ArticleFrontiers in oncology2026
Association between HER2 expression, genomic characteristics, and tumor immune microenvironment dynamics in epithelial ovarian cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the rapid clinical approval of the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing epithelial ovarian cancer (EOC), preclinical mechanistic studies are lacking.The goal of this investigation was to determine the genomic and immunogenic characteristics associated with HER2 expressing EOC in order to better understand the mechanism of treatment response and what subset of patients will benefit most from single agent and combinatorial HER2-directed treatment regimens. Methods: 130 EOC patients were retrospectively identified from our institution's internal clinical genomic database. Selected genomic characteristics were stratified by gastric HER2 score and distributions were analyzed by Fisher's exact test. A subset of 34 EOC tumors were internally HER2 stained and fluorescent immunohistochemistry analysis of PD-L1, CD4, and CD8 was performed. EOC cell lines were treated with T-DXd and Results: Non-significant differences were detected in HRD, Conclusions: HER2 high EOC tumors are more likely to be FOLR1 negative and PD-L1 positive, and treatment with T-DXd downregulates
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.